
NYSE:STZ
This summary was created by AI, based on 2 opinions in the last 12 months.
Constellation Brands Inc. (STZ-N) is scheduled to report its earnings soon, and analysts have mixed views on the company's prospects. One expert expresses optimism in the new CEO, anticipating a subtle improvement in beer and cocktail sales. Conversely, another expert is more pessimistic, highlighting current challenges faced by the company, primarily driven by a decrease in popularity for alcohol stocks and additional external factors such as ICE raids impacting sales in key areas. The stock has seen a notable decline of 36% this year and is trading at a considerably low P/E ratio of 12x. However, this low valuation may be warranted given the ongoing struggles in sales and the emerging impact of GLP-1 drugs, which could affect the alcohol market further.
Last week, it reported stellar numbers but shares still fell, a victim to persistent misconceptions. Their Modelo is the #1 beer in the US and is gaining market share. Pacifico sales are up 21%. STZ operating margins were up 260 basis points. They beat Q1 EPS. Shares should be selling at $300. The problem is STZ also sells hard liquor, which Wall Street has given up on as well as doubts that beer's popularity is waning. Has huge free cash flow, are buying back shares, and is expanding facilities. Other threats are the weight-loss drugs and the popularity of cannabis. He won't abandon this stock though.
He's long owned this, but the stock has hit several road blocks including a bad investment in cannabis-maker Canopy Growth and the company founders selling huge amounts of shares. he's stuck with it, because he believes in their Mexican beers like Modelo. They just reported solid numbers, like an earnings beat, and a sunny forecast about beer sales even wine/spirits isn't doing as well. Is a long way from last year's highs, but is undervalued.
Stock has been sinking for months and faces concerns of the eight-loss drugs impacted their beer sales.